IQ DILI Initiative and the Liver Forum hosted a webinar that will provide an in-depth review and showcasing of the following publications: View Slides

• Review article: Recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patients https://doi.org/10.1111/apt.18271

• IQ DILI Consensus Opinion: Best Practices for Rechallenge Following Suspected Drug-Induced Liver Injury in Clinical Trials https://doi.org/10.1007/s40264-025-01540-x

• The Impact of COVID-19 and COVID-19 Vaccination on Detection, Assessment, and Management of Suspected Acute Drug‐Induced Liver Injury Occurring during Clinical Trials: Consensus Recommendations from the IQ DILI Initiative https://doi.org/10.1007/s40264-025-01591-0

In collaboration with The Liver Forum, IQ DILI held a webinar to provide an in-depth review showcasing recent IQ DILI publications: View Recording | View Slides

• Industry Review of Best Practices for Risk Management of Drug-Induced Liver Injury from Development to Real-World Use. (2023). https://rdcu.be/dpoLd

• Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative. (2024). https://doi.org/10.1007/s40264-023-01390-5

• Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory Therapy. (2024). https://doi.org/10.1007/s40264-024-01399-4